---
type: "Symbol"
title: "SMOC (688265.SH) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/688265.SH/topics.md"
symbol: "688265.SH"
parent: "https://longbridge.com/en/quote/688265.SH.md"
count: 2
datetime: "2026-03-09T10:07:52.459Z"
locales:
  - [en](https://longbridge.com/en/quote/688265.SH/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688265.SH/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688265.SH/topics.md)
---

# SMOC (688265.SH) — Community Discussions

### [模式动物龙头拓展高成长 CRO 赛道，或有意外惊喜？](https://longbridge.com/en/topics/3387325.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2022-08-30T00:31:21.000Z
- Comments: 0
- 在创新药研发服务类企业中，有做 CRO、CDMO 或 CXO 一体化服务的，也有做更细分的分子砌块、药物安全性评价、模式动物等。虽然这些企业都是服务于创新药的研发，但经营业务却没有 “统一范式”。唯一相同的，恐怕就是都依托于自身的优势，谋求打造一体化服务能力。本文就以模式动物领域为例，探讨百奥赛图、南模生物和药康生物差异化的经营模式、业绩表现，以及拓展 CRO 服务的成长逻辑...

### [稀缺的百亿市场！“鼠茅” 与 “猴茅” 的战斗，谁是未来的 10 倍长牛？](https://longbridge.com/en/topics/2674125.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2022-05-27T01:18:22.000Z
- Comments: 0
- 除了高成长以外，稀缺性价值也是诞生牛股的核心要素。正如这几年受新冠疫情的影响，导致全球制药企业 “疯抢” 的小鼠、实验猴等实验动物，就极具稀缺性价值。例如，掌握上游稀缺性实验动物资源的 “猴茅” $JOINN(06127.HK) ，自 2020 年以来股价就曾飙涨超 4 倍，加上相继成功闯关科创板的国内实验动物培育巨头$SMOC(688265.SH) 、拥有 2 万种小鼠模型的 “鼠茅” $GEM

## References

- [SMOC (688265.SH)](https://longbridge.com/en/quote/688265.SH.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688265.SH/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688265.SH/topics.md)